NeuroPace (NPCE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock co
NeuroPace, Inc. NPCE shares soared 6.3% in the last trading session to close at $18.12. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 17.4% gain over the past four weeks.
NeuroPace scored a strong price increase on investors’ optimism surrounding the company’s impending first quarter financial result, which is slated to release on May 12. Per the Zacks Consensus Estimate, the company’s first quarter revenue is projected to be $21.6 million and loss per share is pegged at 19 cents.
This company is expected to post quarterly loss of $0.19 per share in its upcoming report, which represents a year-over-year change of +9.5%. Revenues are expected to be $21.62 million, down 4% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For NeuroPace, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on NPCE going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
For Steris, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $2.89. This represents a change of +5.5% from what the company reported a year ago. Steris currently has a Zacks Rank of #3 (Hold).
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X $TWTR Imaging which shot up +129.6% in little more than 9 months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Join 500,000+ readers who start their day with Quartz.
By subscribing, you agree to our Terms of Service and Privacy Policy.
